Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unapproved hydrocodone crackdown

Executive Summary

FDA is allowing manufacturers of unapproved cough-suppressants containing hydrocodone 30 days to cease production of such products labeled for use in children under six years of age before agency begins enforcement actions. Agency officials estimate there are currently 200 unapproved antitussants containing hydrocodone on the market, compared to seven approved products, suggesting that majority of patients are prescribed unapproved drugs. Reported medication errors based on labeling confusion and formulation differences, neither of which FDA can control for unapproved products, warrant priority enforcement, according to CDER Office of Compliance Director Deborah Autor. FDA is taking stronger enforcement measures against unapproved products following a 2006 compliance policy guide (1"The Pink Sheet" June 12, 2006, p. 10)...

You may also be interested in...



FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions

FDA is encouraging manufacturers of marketed but unapproved drugs to voluntarily submit applications by highlighting the possibility of a de facto exclusivity period for sponsors who receive NDA approval for a drug that other firms are marketing without approval

Japan Regulators Kept On Track Despite Pandemic

While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year. 

QUOTED. 21 January 2021. Larry Biegelsen.

The recently US FDA-cleared Velys robotic-assisted system from DePuy Synthes has distinct features. It also has a small footprint that makes it well-suited for ambulatory surgery centers. See what Larry Biegelsen, an analyst with Wells Fargo, said about it here.

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel